Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Open-Label, Multi-Center Study of Safety, Tolerability, and Efficacy of AFN-12520000 in the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Due to Staphylococci.

Next Previous
Trial Profile

A Phase 2, Open-Label, Multi-Center Study of Safety, Tolerability, and Efficacy of AFN-12520000 in the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Due to Staphylococci.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 04 Jan 2016

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Debio 1452 (Primary)
  • Indications Skin and soft tissue infections; Staphylococcal infections
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Sponsors Affinium Pharmaceuticals

Most Recent Events

  • 28 Dec 2015 Results published in the Antimicrobial Agents and Chemotherapy
  • 13 Sep 2013 Results presented at the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy.
  • 04 Sep 2013 Results will be presented at the 2013 Interscience Conference on Antimicrobial Agents & Chemotherapy (ICAAC-2013) according to an Affinium Pharmaceuticals media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top